{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:56:55Z","timestamp":1790582215430,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.abd.2026.501449","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:28:23Z","timestamp":1787984903000},"page":"501449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical practice guideline for psoriasis management in Latin America"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-9347","authenticated-orcid":false,"given":"Fernando","family":"Valenzuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-2684","authenticated-orcid":false,"given":"Juan Ra\u00fal","family":"Castro Ayarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5105-807X","authenticated-orcid":false,"given":"D\u00e9bora","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-9972","authenticated-orcid":false,"given":"Angela Mar\u00eda","family":"Londo\u00f1o-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3334-0859","authenticated-orcid":false,"given":"Karla del Roc\u00edo","family":"Mac\u00edas Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7033-2337","authenticated-orcid":false,"given":"Gabriel","family":"Magari\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-1076","authenticated-orcid":false,"given":"Enrique Salvador","family":"Rivas Z\u00e1ldivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1173-8292","authenticated-orcid":false,"given":"Manuel","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-9565","authenticated-orcid":false,"given":"Sara","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-482X","authenticated-orcid":false,"given":"Carolina","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-107X","authenticated-orcid":false,"given":"Paola Jimena","family":"C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-6183","authenticated-orcid":false,"given":"Carla","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-932X","authenticated-orcid":false,"given":"Renata","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-3408","authenticated-orcid":false,"given":"Susan","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-7313","authenticated-orcid":false,"given":"Linda","family":"Ibat\u00e1 Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-3316","authenticated-orcid":false,"given":"Julieth Carolina","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7404-3860","authenticated-orcid":false,"given":"Jorge","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2026.501449_bib0005","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.abd.2026.501449_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1590\/abd1806-4841.20186069","article-title":"The association between psoriasis and health-related quality of life, work productivity, and healthcare resource use in Brazil","volume":"93","author":"DiBonaventura","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0025","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jdv.14393","article-title":"Psoriasis in Latin America and the Caribbean: a systematic review","volume":"31","author":"Hern\u00e1ndez-V\u00e1squez","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0030","doi-asserted-by":"crossref","DOI":"10.5867\/medwave.2022.08.002564","article-title":"Epidemiologic characteristics and burden of psoriasis: a multicenter, cross-sectional study","volume":"22","author":"Sanclemente","year":"2022","journal-title":"Medwave"},{"key":"10.1016\/j.abd.2026.501449_bib0035","doi-asserted-by":"crossref","first-page":"T339","DOI":"10.1016\/j.ad.2022.02.017","article-title":"Prevalence of psoriasis in Colombia according to the national health registry","volume":"113","author":"Fern\u00e1ndez-\u00c1vila","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2026.501449_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.abd.2026.501449_bib0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.vhri.2021.05.004","article-title":"Burden of disease for psoriasis in Argentina, Brazil, Colombia, and Mexico","volume":"26","author":"Papadimitropoulos","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.abd.2026.501449_bib0050","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s12325-019-01049-7","article-title":"Humanistic and economic impact of moderate to severe plaque psoriasis in Brazil","volume":"36","author":"Lopes","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/bjd\/ljac128","article-title":"Access to psoriasis treatment in Brazil and Chile: a cross-sectional multicentre global healthcare study on psoriasis","volume":"188","author":"Maul","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.abd.2023.04.006","article-title":"Unmet needs in the management of psoriasis in Latin America: a systematic review","volume":"99","author":"Schoenardie","year":"2024","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.abd.2025.501242","article-title":"Highlights of the Brazilian Society of Dermatology\u2019s Brazilian Consensus on Psoriasis","volume":"100","author":"Romiti","year":"2025","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.abd.2026.501449_bib0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.abd.2026.501449_bib0080","series-title":"Conflict of Interest in Medical Research, Education, and Practice","year":"2009"},{"key":"10.1016\/j.abd.2026.501449_bib0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.abd.2026.501449_bib0090","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024) [Internet]","year":"2024"},{"key":"10.1016\/j.abd.2026.501449_bib0095","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.abd.2026.501449_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol."},{"key":"10.1016\/j.abd.2026.501449_bib0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.abd.2026.501449_bib0110","series-title":"Joanna Briggs Institute [Internet]","year":"2025"},{"key":"10.1016\/j.abd.2026.501449_bib0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.abd.2026.501449_bib0120","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.abd.2026.501449_bib0125","series-title":"Gu\u00eda metodol\u00f3gica para la elaboraci\u00f3n de gu\u00edas de pr\u00e1ctica cl\u00ednica con evaluaci\u00f3n econ\u00f3mica en el Sistema General de Seguridad Social en Salud Colombiano [Internet]","year":"2014"},{"key":"10.1016\/j.abd.2026.501449_bib0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmjebm-2022-111962","article-title":"Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance","volume":"28","author":"Dewidar","year":"2023","journal-title":"BMJ Evid-Based Med"},{"key":"10.1016\/j.abd.2026.501449_bib0135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab","volume":"28","author":"Elewski","year":"2017","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year","volume":"33","author":"Yasmeen","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0145","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","article-title":"Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document","volume":"53","author":"Belinch\u00f3n Romero","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.abd.2026.501449_bib0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14712598.2021.1849131","article-title":"Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies","volume":"21","author":"Galluzzo","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0155","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/09546634.2020.1720578","article-title":"In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity","volume":"32","author":"Rusk","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0160","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/07853890.2023.2192957","article-title":"Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review","volume":"55","author":"Belinchon Romero","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.abd.2026.501449_bib0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3899\/jrheum.150638","article-title":"Concept of remission in chronic plaque psoriasis","volume":"93","author":"Gisondi","year":"2015","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.abd.2026.501449_bib0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI 90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0175","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40257-024-00874-z","article-title":"Sequencing of targeted therapy in psoriasis: does it matter?","volume":"25","author":"Boswell","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jdermsci.2022.02.007","article-title":"Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study","volume":"105","author":"Imafuku","year":"2022","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.abd.2026.501449_bib0185","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1111\/jdv.17520","article-title":"Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis","volume":"35","author":"Reich","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0190","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1684\/ejd.2021.4150","article-title":"Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study","volume":"31","author":"Campanati","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.06.274","article-title":"25572 Impact of risankizumab on the duration of PASI90 achievement: a post hoc analysis of 4 phase III clinical trials","volume":"85","author":"Lebwohl","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0200","first-page":"18","article-title":"Early treatment targets for predicting long-term dermatology life quality index response in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis from a long-term clinical study","volume":"13","author":"Puig","year":"2020","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0205","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2340\/00015555-3245","article-title":"Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes","volume":"99","author":"Puig","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0210","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.jid.2018.01.041","article-title":"Evaluation of sPGA \u00d7 BSA as an Outcome Measure and Treatment Target for Clinical Practice","volume":"138","author":"Merola","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0215","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1111\/jdv.18783","article-title":"Long\u2010term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years","volume":"37","author":"Tha\u00e7i","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2026.501449_bib0230","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ijd.14471","article-title":"Latin American clinical practice guidelines on the systemic treatment of psoriasis SOLAPSO-Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)","volume":"58","author":"Kogan","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0235","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1080\/09546634.2022.2117539","article-title":"Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review","volume":"33","author":"van Huizen","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0240","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0245","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13555-023-00903-5","article-title":"Combination therapy for psoriasis with methotrexate and other oral disease-modifying antirheumatic drugs: a systematic review","volume":"13","author":"Hsieh","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0250","article-title":"Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis","author":"Cheng","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2026.501449_bib0255","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.696597","article-title":"Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease","volume":"8","author":"Arora","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.abd.2026.501449_bib0260","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2026.501449_bib0265","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.625755","article-title":"Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis","volume":"7","author":"Mourad","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.abd.2026.501449_bib0270","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.abd.2026.501449_bib0275","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0280","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/JD9.0000000000000395","article-title":"Tyrosine kinase-2 inhibitor (deucravacitinib) for psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"7","author":"Mahmoud","year":"2024","journal-title":"Int J Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021537","article-title":"Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2026.501449_bib0290","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0295","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2249145","article-title":"Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis","volume":"34","author":"Li","year":"2023","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14712598.2021.1958778","article-title":"A systematic review on infliximab biosimilar SB2: from pre-clinical data to real-world evidence","volume":"22","author":"Macaluso","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0305","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2026.501449_bib0315","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0320","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14857","article-title":"Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review","volume":"34","author":"Camela","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0325","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/03007995.2023.2288280","article-title":"Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis","volume":"40","author":"Tsiogkas","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.abd.2026.501449_bib0335","doi-asserted-by":"crossref","first-page":"s420","DOI":"10.25251\/skin.8.supp.420","volume":"8","author":"Duffin","year":"2024","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.abd.2026.501449_bib0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/24755303231217491","article-title":"Assessing comparative efficacy of biologics for the treatment of psoriasis with nail involvement: a systematic review","volume":"9","author":"Khan","year":"2024","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.abd.2026.501449_bib0345","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40257-023-00786-4","article-title":"Efficacy and safety of nail psoriasis targeted therapies: a systematic review","volume":"24","author":"Hwang","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0350","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s13555-021-00536-6","article-title":"Genital and inverse\/intertriginous psoriasis: an updated review of therapies and recommendations for practical management","volume":"11","author":"Hong","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0355","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","article-title":"Treatment of genital psoriasis: a systematic review","volume":"8","author":"Beck","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0360","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/1744666X.2023.2272049","article-title":"Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis","volume":"19","author":"Tsiogkas","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.abd.2026.501449_bib0365","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40257-024-00849-0","article-title":"Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111716","article-title":"Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis","volume":"130","author":"Xia","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.abd.2026.501449_bib0375","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s13555-024-01228-7","article-title":"Clinical characteristics and disease burden of patients with moderate-to-severe generalized pustular psoriasis flares in Taiwan","volume":"14","author":"Lu","year":"2024","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/09546634.2019.1689228","article-title":"A systematic review of treatment strategies for erythrodermic psoriasis","volume":"32","author":"Reynolds","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0385","first-page":"59","article-title":"Updates on the treatment of erythrodermic psoriasis","volume":"11","author":"Lo","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.abd.2026.501449_bib0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaad.2020.03.073","article-title":"Treatment of erythrodermic psoriasis with biologics: a systematic review","volume":"83","author":"Carrasquillo","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0395","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/12034754241266187","article-title":"Management of guttate psoriasis: a systematic review","volume":"28","author":"Zhou","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2026.501449_bib0400","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Adv Dermatol Allergol Dermatol Alergol"},{"key":"10.1016\/j.abd.2026.501449_bib0405","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jdv.19238","article-title":"Exposure to biologic therapy before and during pregnancy in patients with psoriasis: systematic review and meta-analysis","volume":"37","author":"S\u00e1nchez-Garc\u00eda","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501449_bib0410","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study","volume":"186","author":"Jeong","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.abd.2026.501449_bib0415","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/jcm13071940","article-title":"Biological therapy for psoriasis in cancer patients: an 8-year retrospective real-life study","volume":"13","author":"Battista","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.abd.2026.501449_bib0420","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","article-title":"Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta-analysis","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2026.501449_bib0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2026.501449_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000002863","article-title":"The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis","volume":"37","author":"Alhalabi","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2026.501449_bib0435","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10238-022-00827-y","article-title":"Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.abd.2026.501449_bib0440","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/v17010042","article-title":"Incidence of HBV reactivation in psoriasis patients undergoing cytokine inhibitor therapy: a single-center study and systematic review with a meta-analysis","volume":"17","author":"Kuo","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.abd.2026.501449_bib0445","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.piel.2023.08.003","article-title":"Experiencia en el uso de terapia biol\u00f3gica en pacientes con infecci\u00f3n por el virus de la inmunodeficiencia humana y psoriasis","volume":"39","author":"Villa-M\u00e9ndez","year":"2024","journal-title":"Piel"},{"key":"10.1016\/j.abd.2026.501449_bib0450","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s12325-024-02873-2","article-title":"Management of psoriasis patients with serious infectious diseases","volume":"41","author":"Megna","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106226","article-title":"Risk for latent tuberculosis infection reactivation among patients with psoriasis on biologics treatment: a meta-analysis","volume":"89","author":"Zhu","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.abd.2026.501449_bib0460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/PTT.S510141","article-title":"Infection risk and vaccination in the management of psoriasis: considerations for biologic therapy","author":"Mateu-Arrom","year":"2025","journal-title":"Psoriasis Targets Ther"},{"key":"10.1016\/j.abd.2026.501449_bib0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jdermsci.2016.11.008","article-title":"Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes","volume":"85","author":"Wang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.abd.2026.501449_bib0470","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s10787-025-01675-4","article-title":"Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors","volume":"33","author":"Jafarzadeh","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.abd.2026.501449_bib0475","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-023-00782-8","article-title":"Secukinumab in pediatric patients with plaque psoriasis: pooled safety analysis from two phase 3 randomized clinical trials","volume":"24","author":"Sticherling","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","volume":"40","author":"Siegfried","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.abd.2026.501449_bib0485","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clnu.2025.02.005","article-title":"Evidence-based dietary recommendations for patients with psoriasis: a systematic review","volume":"47","author":"Wang","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.abd.2026.501449_bib0490","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s12529-024-10315-0","article-title":"Effect of psychological intervention on quality of life among patients with psoriasis: a meta-analysis","volume":"31","author":"Wei","year":"2024","journal-title":"Int J Behav Med"},{"key":"10.1016\/j.abd.2026.501449_bib0495","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2427321","article-title":"Psychosocial interventions for psoriasis: a Bayesian network meta-analysis","volume":"36","author":"Lu","year":"2025","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2026.501449_bib0500","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/jocd.16299","article-title":"Efficacy of probiotic supplementation in the treatment of psoriasis-a systematic review and meta-analysis","volume":"23","author":"Wei","year":"2024","journal-title":"J Cosmet Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:26:11Z","timestamp":1790580371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059626001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0365059626001625"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2026.501449","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical practice guideline for psoriasis management in Latin America","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2026.501449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501449"}}